Am J Psychiatry 156:419-425, March 1999
©Copyright 1999 American Psychiatric Association
Placebo-Controlled Study of the D4/5-HT2A Antagonist Fananserin in the Treatment of Schizophrenia
Philippe Truffinet, M.D.,
Carol A. Tamminga, M.D.,
Louis F. Fabre, M.D., Ph.D.,
Herbert Y. Meltzer, M.D.,
Marie-Emmanuelle Rivière, Ph.D., and
Catherine Papillon-Downey
OBJECTIVE: The authors' objective was to assess the potential efficacy of fananserin (RP62203), a potent antagonist at the D4 and serotonin2A (5-HT2A) receptors, on symptoms of schizophrenia. METHOD: A double-blind, placebo-controlled study was conducted in 97 patients. Doses of fananserin reached 250 mg b.i.d. over 28 days, starting with an 8-day escalation. Most of the patients were men with paranoid schizophrenia; they were approximately 38 years old. The primary outcome measure was the total Positive and Negative Syndrome Scale score. The patients' mean score on the Positive and Negative Syndrome Scale at entry was 91.8 (SD=16.5). A low dropout rate was observed in both groups of patients (19 [30%] of those given fananserin and nine [27%] of those given placebo). RESULTS: The total Positive and Negative Syndrome Scale score of the patients given fananserin decreased at endpoint by a mean of 4.2 points (SD=15.4); the score of the patients given placebo decreased by 6.7 points (SD=19.6). No differences between treatments were found on secondary measures such as the Clinical Global Impression, Positive and Negative Syndrome Scale subscores or individual items, and Brief Psychiatric Rating Scale total score. The patients' extrapyramidal symptoms did not worsen during the trial, but the patients given fananserin had an increase in akathisia. The safety profile was good in both groups of patients. CONCLUSIONS: The results of this study do not support the prediction that a selective D4 antagonist associated with strong 5-HT2A antagonism will exhibit an antipsychotic effect. (Am J Psychiatry 1999; 156:419–425)
This article has been cited by other articles:
|
|
|
|
 
J. A. Gray and B. L. Roth
Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia
Schizophr Bull,
September 1, 2007;
33(5):
1100 - 1119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Tauscher, T. Hussain, O. Agid, N. P. L.G. Verhoeff, A. A. Wilson, S. Houle, G. Remington, R. B. Zipursky, and S. Kapur
Equivalent Occupancy of Dopamine D1 and D2 Receptors With Clozapine: Differentiation From Other Atypical Antipsychotics
Am J Psychiatry,
September 1, 2004;
161(9):
1620 - 1625.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Wang and P. S. Goldman-Rakic
D2 receptor regulation of synaptic burst firing in prefrontal cortical pyramidal neurons
PNAS,
April 6, 2004;
101(14):
5093 - 5098.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. G. Costa, L. Steardo, and V. Cuomo
Structural Effects and Neurofunctional Sequelae of Developmental Exposure to Psychotherapeutic Drugs: Experimental and Clinical Aspects
Pharmacol. Rev.,
March 1, 2004;
56(1):
103 - 147.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Stevens
Schizophrenia: Reproductive Hormones and the Brain
Am J Psychiatry,
May 1, 2002;
159(5):
713 - 719.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kapur and P. Seeman
Does Fast Dissociation From the Dopamine D2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis
Am J Psychiatry,
March 1, 2001;
158(3):
360 - 369.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Kapur, R. Zipursky, C. Jones, C. S. Shammi, G. Remington, and P. Seeman
A Positron Emission Tomography Study of Quetiapine in Schizophrenia: A Preliminary Finding of an Antipsychotic Effect With Only Transiently High Dopamine D2 Receptor Occupancy
Arch Gen Psychiatry,
June 1, 2000;
57(6):
553 - 559.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1999
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
